US 11,700,840 B2
L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
Kenneth Rodgers, Sydney (AU); Rachael Dunlop, Sydney (AU); and Paul A. Cox, Jackson Hole, WY (US)
Assigned to THE INSTITUTE FOR ETHNOMEDICINE, Jackson, WY (US)
Filed by THE INSTITUTE FOR ETHNOMEDICINE, Provo, UT (US)
Filed on Oct. 6, 2017, as Appl. No. 15/727,335.
Application 15/727,335 is a continuation of application No. 13/683,821, filed on Nov. 21, 2012, abandoned.
Claims priority of provisional application 61/562,194, filed on Nov. 21, 2011.
Prior Publication US 2018/0027781 A1, Feb. 1, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/198 (2006.01); A61K 38/00 (2006.01); A61K 31/195 (2006.01); A61P 25/28 (2006.01); A61P 25/00 (2006.01); A61P 25/16 (2006.01); A01K 67/027 (2006.01); A61P 43/00 (2006.01)
CPC A01K 67/027 (2013.01) [A61K 31/198 (2013.01); A61K 38/00 (2013.01); A61P 25/00 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); A61P 43/00 (2018.01)] 21 Claims
 
1. A method of inhibiting or reducing incorporation of β-N-methylamino-L-alanine (BMAA), 2,4-diaminobutyric acid (2,4-DAB), 2,3-diaminobutyric acid (2,3-DAB), N-(2-aminoethyl)glycine (AEG) or β-N-methyl-alanine (BAMA) into one or more proteins of a mammalian cell in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutical composition consisting essentially of:
(1) an active ingredient selected from the group consisting of L-serine, a salt of L-serine and an L-serine ester; and
(2) at least one pharmaceutically acceptable carrier or excipient;
wherein the pharmaceutical composition includes the active ingredient in an amount of from 10 to 50 grams per day, and
wherein the active ingredient is sufficient to inhibit or reduce incorporation of β-N-methylamino-L-alanine (BMAA), 2,4-diaminobutyric acid (2,4-DAB), 2,3-diaminobutyric acid (2,3-DAB), N-(2-aminoethyl)glycine (AEG) or β-amino-N-methyl-alanine (BAMA), into the one or more proteins of the mammalian cell.